Literature DB >> 17401192

Complex structure of a bacterial class 2 histone deacetylase homologue with a trifluoromethylketone inhibitor.

Tine Kragh Nielsen1, Christian Hildmann, Daniel Riester, Dennis Wegener, Andreas Schwienhorst, Ralf Ficner.   

Abstract

Histone deacetylases (HDACs) have emerged as attractive targets in anticancer drug development. To date, a number of HDAC inhibitors have been developed and most of them are hydroxamic acid derivatives, typified by suberoylanilide hydroxamic acid (SAHA). Not surprisingly, structural information that can greatly enhance the design of novel HDAC inhibitors is so far only available for hydroxamic acids in complex with HDAC or HDAC-like enzymes. Here, the first structure of an enzyme complex with a nonhydroxamate HDAC inhibitor is presented. The structure of the trifluoromethyl ketone inhibitor 9,9,9-trifluoro-8-oxo-N-phenylnonanamide in complex with bacterial FB188 HDAH (histone deacetylase-like amidohydrolase from Bordetella/Alcaligenes strain FB188) has been determined. HDAH reveals high sequential and functional homology to human class 2 HDACs and a high structural homology to human class 1 HDACs. Comparison with the structure of HDAH in complex with SAHA reveals that the two inhibitors superimpose well. However, significant differences in binding to the active site of HDAH were observed. In the presented structure the O atom of the trifluoromethyl ketone moiety is within binding distance of the Zn atom of the enzyme and the F atoms participate in interactions with the enzyme, thereby involving more amino acids in enzyme-inhibitor binding.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17401192      PMCID: PMC2330214          DOI: 10.1107/S1744309107012377

Source DB:  PubMed          Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun        ISSN: 1744-3091


  24 in total

1.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

2.  Refinement of macromolecular structures by the maximum-likelihood method.

Authors:  G N Murshudov; A A Vagin; E J Dodson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1997-05-01

Review 3.  Histone deacetylase inhibitors in cancer therapy.

Authors:  Roberto R Rosato; Steven Grant
Journal:  Cancer Biol Ther       Date:  2003 Jan-Feb       Impact factor: 4.742

4.  Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.

Authors:  M S Finnin; J R Donigian; A Cohen; V M Richon; R A Rifkind; P A Marks; R Breslow; N P Pavletich
Journal:  Nature       Date:  1999-09-09       Impact factor: 49.962

5.  Crystal structure of a bacterial class 2 histone deacetylase homologue.

Authors:  Tine Kragh Nielsen; Christian Hildmann; Achim Dickmanns; Andreas Schwienhorst; Ralf Ficner
Journal:  J Mol Biol       Date:  2005-10-07       Impact factor: 5.469

Review 6.  Juvenile hormone (JH) esterase: why are you so JH specific?

Authors:  Shizuo G Kamita; Andrew C Hinton; Craig E Wheelock; Mark D Wogulis; David K Wilson; Nicola M Wolf; Jeanette E Stok; Bertold Hock; Bruce D Hammock
Journal:  Insect Biochem Mol Biol       Date:  2003-12       Impact factor: 4.714

Review 7.  Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.

Authors:  Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

8.  Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases.

Authors:  John R Somoza; Robert J Skene; Bradley A Katz; Clifford Mol; Joseph D Ho; Andy J Jennings; Christine Luong; Andrew Arvai; Joseph J Buggy; Ellen Chi; Jie Tang; Bi-Ching Sang; Erik Verner; Robert Wynands; Ellen M Leahy; Douglas R Dougan; Gyorgy Snell; Marc Navre; Mark W Knuth; Ronald V Swanson; Duncan E McRee; Leslie W Tari
Journal:  Structure       Date:  2004-07       Impact factor: 5.006

9.  Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor.

Authors:  Alessandro Vannini; Cinzia Volpari; Gessica Filocamo; Elena Caroli Casavola; Mirko Brunetti; Debora Renzoni; Prasun Chakravarty; Chantal Paolini; Raffaele De Francesco; Paola Gallinari; Christian Steinkühler; Stefania Di Marco
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 10.  Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.

Authors:  Giliane Bouchain; Daniel Delorme
Journal:  Curr Med Chem       Date:  2003-11       Impact factor: 4.530

View more
  6 in total

1.  Epigenetic actions of environmental factors and promising drugs for cancer therapy.

Authors:  Zhong-Tian Bai; Bing Bai; Jun Zhu; Cui-Xia Di; Xun Li; Wen-Ce Zhou
Journal:  Oncol Lett       Date:  2017-12-13       Impact factor: 2.967

2.  Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity.

Authors:  Anja Schuetz; Jinrong Min; Abdellah Allali-Hassani; Matthieu Schapira; Michael Shuen; Peter Loppnau; Ralph Mazitschek; Nick P Kwiatkowski; Timothy A Lewis; Rebecca L Maglathin; Thomas H McLean; Alexey Bochkarev; Alexander N Plotnikov; Masoud Vedadi; Cheryl H Arrowsmith
Journal:  J Biol Chem       Date:  2008-02-19       Impact factor: 5.157

3.  Inhibition of DD-peptidases by a specific trifluoroketone: crystal structure of a complex with the Actinomadura R39 DD-peptidase.

Authors:  Liudmila Dzhekieva; S A Adediran; Raphael Herman; Frédéric Kerff; Colette Duez; Paulette Charlier; Eric Sauvage; R F Pratt
Journal:  Biochemistry       Date:  2013-03-13       Impact factor: 3.162

4.  Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain.

Authors:  Matthew J Bottomley; Paola Lo Surdo; Paolo Di Giovine; Agostino Cirillo; Rita Scarpelli; Federica Ferrigno; Philip Jones; Petra Neddermann; Raffaele De Francesco; Christian Steinkühler; Paola Gallinari; Andrea Carfí
Journal:  J Biol Chem       Date:  2008-07-08       Impact factor: 5.157

Review 5.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

6.  Substrate specificity and function of acetylpolyamine amidohydrolases from Pseudomonas aeruginosa.

Authors:  Andreas Krämer; Jan Herzer; Joerg Overhage; Franz-Josef Meyer-Almes
Journal:  BMC Biochem       Date:  2016-03-09       Impact factor: 4.059

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.